WO2026120507 - AN ANTIBODY-DRUG CONJUGATE FOR USE IN THE TREATMENT OF DRUG-RESISTANT CANCER
National phase entry is expected:
Publication Number
WO/2026/120507
Publication Date
11.06.2026
International Application No.
PCT/IB2025/062383
International Filing Date
03.12.2025
Title **
[English]
AN ANTIBODY-DRUG CONJUGATE FOR USE IN THE TREATMENT OF DRUG-RESISTANT CANCER
[French]
CONJUGUÉ ANTICORPS-MÉDICAMENT DESTINÉ À ÊTRE UTILISÉ DANS LE TRAITEMENT DU CANCER RÉSISTANT AUX MÉDICAMENTS
Applicants **
DAIICHI SANKYO COMPANY, LIMITED
Inventors
NAGASE, Shotaro
Priority Data
2024-210960
04.12.2024
JP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4851 | |
| EPO | Filing, Examination, Granting | 53940 | |
| Japan | Filing, Examination, Granting | 3791 | |
| South Korea | Filing, Examination, Granting | 5403 | |
| USA | Filing, Examination, Granting | 28890 |
Total:
96,875
Contact Us
Abstract[English]
A pharmaceutical composition for use in treating cancer comprising an anti-CDH6 antibody-drug conjugate. The anti-CDH6 antibody-drug conjugate comprises an anti-CDH6 antibody or an antigen-binding fragment thereof that specifically binds to the amino acid sequence of the EC3 domain of CDH6 shown in SEQ ID NO: 1. One of the following applies: (i) the cancer is resistant to an anti-FOLR1 antibody-drug conjugate; (ii) the cancer is resistant to a regimen comprising an anti-FOLR1 antibody-drug conjugate; (iii) the cancer is a recurrence of a cancer previously treated with a regimen comprising an anti-FOLR1 antibody-drug conjugate; or (iv) the cancer was previously treated with a regimen comprising an anti-FOLR1 antibody-drug conjugate.[French]
L'invention concerne une composition pharmaceutique destinée à être utilisée dans le traitement du cancer comprenant un conjugué anticorps anti-CDH6-médicament. Le conjugué anticorps anti-CDH6-médicament comprend un anticorps anti-CDH6 ou un fragment de liaison à l'antigène de celui-ci qui se lie spécifiquement à la séquence d'acides aminés du domaine EC3 de CDH6 représenté dans SEQ ID NO : 1. L'une des situations suivantes s'applique : (i) le cancer est résistant à un conjugué anticorps anti-FOLR1-médicament ; (ii) le cancer est résistant à un régime comprenant un conjugué anticorps anti-FOLR1-médicament ; (iii) le cancer est une récurrence d'un cancer précédemment traité avec un régime comprenant un conjugué anticorps anti-FOLR1-médicament ; ou (iv) le cancer a été préalablement traité avec un régime comprenant un conjugué anticorps anti-FOLR1-médicament.